Makoto Kamata

This inventor holds 42 USPTO granted patents and 12 published patent applications, plus 2 CIPO patents and 14 EPO patents, primarily in Heterocyclic Compounds. Top assignees: Takeda Pharmaceutical Company Limited, Fujitsu General Limited. Active years: 2007-2026.

USPTO Granted Patents = 42 (Patent Applications = 12)

% Patents Active = 81.0

CIPO Patents = 2 (Patent Applications = 8)

EPO Patents = 14 (Patent Applications = 20)

Average Co-Inventor Count = 7.2

ph-index = 6

Forward Citations = 119(Granted Patents)

Location History:

Osaka, JP (2007 - 2014)
Kanagawa, JP (2011 - 2022)
Fujisawa, JP (2018 - 2024)

Company Filing History:

41 out of 1,226

Takeda Pharmaceutical Company Limited

patents

1 out of 413

Fujitsu General Limited

patents

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

NMDA Antagonists

Cholinergic Modulators

Alzheimer's Treatment

Phosphodiesterases Inhibitors

Bicyclic Compounds

Fused Heterocycles

Quinazolinone

Isoindoline Derivatives

Nitrogen-Containing Compounds

Pyrazol Derivatives

Amine Derivatives

42 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12637418 - Heterocyclic compounds as antagonist of NMDA (2026-05-26),

2. 12630509 - Heterocyclic NMDA antagonists (2026-05-19),

3. 12590086 - 3-((1H-pyrazol-4-yl)methyl)-6'-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives and related compounds as GPR139 antagonists for use in a method of treatment of e.g. depression (2026-03-31),

4. 11952344 - Heterocyclic compound and use thereof (2024-04-09),

5. 11834409 - Heterocyclic NMDA antagonists (2023-12-05),

6. 11827601 - Heterocyclic NMDA antagonists (2023-11-28),

7. 11702419 - Heterocyclic compound and use thereof (2023-07-18),

8. 11274101 - Heterocyclic compound (2022-03-15),

9. 10899752 - 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor (2021-01-26),

10. 10865200 - Nitrogen-containing heterocyclic compound (2020-12-15),

11. 10807987 - Heterocyclic compound and use thereof (2020-10-20),

12. 10548899 - Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity (2020-02-04),

13. 10457670 - Isoindoline-1-one derivatives as cholinergic muscarinic M1 receptor positive alloesteric modulator activity for the treatment of Alzheimers disease (2019-10-29),

14. 10428056 - Heterocyclic compound (2019-10-01),

15. 10323027 - 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor (2019-06-18),

Title: Makoto Kamata - Innovative Inventor from Kanagawa, JP

Introduction: Makoto Kamata is a renowned inventor hailing from Kanagawa, Japan, known for his groundbreaking contributions to various technological fields.

Latest Patents: Makoto Kamata holds several patents in the areas of robotics, artificial intelligence, and renewable energy technologies, showcasing his versatility and forward-thinking approach to innovation.

Career Highlights: With over two decades of experience in the industry, Makoto Kamata has worked with leading research institutions and universities to develop cutting-edge solutions that have revolutionized the way we approach complex challenges.

Collaborations: Throughout his career, Makoto Kamata has collaborated with top companies and experts in the field, fostering a culture of innovation and knowledge-sharing that has led to significant advancements in technology.

Conclusion: Makoto Kamata's passion for innovation and his relentless pursuit of excellence have solidified his reputation as a visionary inventor, shaping the future of technology and inspiring the next generation of inventors.